VOLUNTARY ANNOUNCEMENT - AUMOLERTINIB MESILATE TABLETS WAS APPROVED BY THE MHRA FOR MARKETING

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2025

INSIDE INFORMATION - LICENSE AGREEMENT WITH REGENERON

VOLUNTARY ANNOUNCEMENT - THE THIRD BIOLOGICS LICENSE APPLICATION OF XINYUE (INEBILIZUMAB INJECTION) WAS ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

NOTIFICATION LETTER TO NON-REGISTERED HOLDERS AND REQUEST FORM

NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS AND REPLY FORM

FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, JUNE 20, 2025

NOTICE OF ANNUAL GENERAL MEETING

(1) PROPOSED RE-ELECTION OF DIRECTORS, (2) PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE SHARES, (3) PROPOSED DECLARATION OF FINAL DIVIDEND, (4) PROPOSED RE-APPOINTMENT OF AUDITORS AND (5) NOTICE OF ANNUAL GENERAL MEETING

VOLUNTARY ANNOUNCEMENT - THE CLINICAL TRIAL APPROVAL FOR HS-10510 TABLETS ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

VOLUNTARY ANNOUNCEMENT - THE CLINICAL TRIAL APPROVAL FOR HS-10542 CAPSULES ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

VOLUNTARY ANNOUNCEMENT - THE CLINICAL TRIAL APPROVAL FOR HS-20118 TABLETS ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION